GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
03. Dezember 2024 08:30 ET
|
GlucoTrack, Inc.
Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks Rutherford, NJ, Dec. 03, 2024 (GLOBE NEWSWIRE) --...
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
14. November 2024 16:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for...
Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering
13. November 2024 09:00 ET
|
GlucoTrack, Inc.
Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for...
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
22. Oktober 2024 09:00 ET
|
GlucoTrack, Inc.
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK)...
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
01. Oktober 2024 09:00 ET
|
GlucoTrack, Inc.
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference Rutherford, NJ, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc....
JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
03. September 2024 09:00 ET
|
GlucoTrack, Inc.
Biotech veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) --...
GLUCOTRACK ANNOUNCES NEW VICE PRESIDENT OF CLINICAL OPERATIONS
27. August 2024 09:00 ET
|
GlucoTrack, Inc.
Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack,...
Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
15. August 2024 09:00 ET
|
GlucoTrack, Inc.
Glucotrack ADCES poster highlights over 50% of surveyed diabetes patients are open to new Continuous Blood Glucose Monitor concept Rutherford, NJ, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc....
GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE
05. August 2024 09:00 ET
|
GlucoTrack, Inc.
Market research data shows interest in additional glucose monitoring options for people with diabetes who use insulin Rutherford, NJ, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq:...
GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR
31. Juli 2024 16:00 ET
|
GlucoTrack, Inc.
Rutherford, NJ, July 31, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and...